AU Patent

AU2018284335A1 — Treatment of depression with NMDA antagonists and D2/5HT2A or selective 5HT2A antagonists

Assigned to Glytech LLC · Expires 2020-01-30 · 6y expired

What this patent protects

Patent listed against pimavanserin-tartrate.

Drugs covered by this patent

pimavanserin-tartrate (PIMAVANSERIN TARTRATE)

Patent Metadata

Patent number: AU2018284335A1
Jurisdiction: AU
Classification: —
Expires: 2020-01-30
Drug substance claim: No
Drug product claim: No
Assignee: Glytech LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.